Evaluation of some ocular surface characteristics before and after trabeculectomy

Session Details

Session Title: Presented Poster Session: Glaucoma I

Venue: Poster Village: Pod 3

First Author: : A.Antonova RUSSIA

Co Author(s): :    V. Nikolaenko                       

Abstract Details

Purpose:

Glaucoma is the leading cause of global irreversible blindness. Prevalence of glaucoma in the population aged 40–80 years is 3.54%. In 2013, the number of people (aged 40–80 years) with glaucoma worldwide was estimated to be 64.3 million, increasing to 76.0 million in 2020 and 111.8 million in 2040. From 52.6 to 84% of patients receiving hypotensive (both mono- and combined) therapy accompanies «dry eye» syndrome (DES).

Setting:

Evaluation of some ocular surface characteristics before and after trabeculectomy.

Methods:

The study involved 357 patients, of whom 246 (92 men and 154 women) were monitored for at least 6 months after surgery. The average age of the group was 70.8 ± 7.35 years. Estimation of the main parameters was carried out before the operation, as well as 1, 3 and 6 months after TE. All patients have a standard ophthalmologic examination; Ocular Surface Disease Index (OSDI) definition; calculation of the integral indicator of subjective discomfort (IISD) (by Brzhesky V.V., Somov E.E., 2003), tear film Break Up Time (TBUT) and Schirmer I test.

Results:

The preoperative IISD decreased from 4 ± 2.54 to 2 ± 1.64 points in 3 months. In the long-term period it was 3 ± 2.04 points. The OSDI significantly decreased from 9.14 ± 5.85 points to 5.53 ± 4.91 and 5.85 ± 4.89 points (6 months after surgery). The TBUT before TE, equal to 10 ± 4.83 sec, after 3 months increased to 12 ± 5.03 sec, and after 6 months - up to 13 ± 4.92 sec. The Schirmer I sample in the preoperative period and after 6 months remained at the same level - 14.0 ± 5.1 mm.

Conclusions:

) Improvement of the ocular surface is noted a month after the operation. The disappearance of the pharmacological load after TE is accompanied by a regression of the symptoms and clinical signs of DES, which helps to improve the quality of life of patients with glaucoma.

Financial Disclosure:

None